Dr. Sharon Cohen is a behavioural neurologist and medical director of Toronto Memory Program. She is known for excellence in patient care, teaching and clinical research. She holds an FRCPC in neurology from the Royal College of Physicians and Surgeons of Canada. Her research trial site is the most active in the country and has contributed to over 100 international treatment studies, providing direct study participation to over 2,500 Canadian patients and their families.
Currently three studies are underway to investigate whether a research drug called idalopirdine, given in addition to the Alzheimer's medicine donepezil, rivastigmine or galantamine, improves brain functioning in areas such as memory, thinking and reasoning.